Oncology biotech Black Diamond Therapeutics sets terms for $151 million IPO - (NASDAQ via NewsPoints Desk)

  • Black Diamond Therapeutics announced plans to raise $151 million by offering 8.9 million shares at a price range of $16 to $18, reported NASDAQ.

  • The Phase I-ready biotechnology is developing targeted kinase inhibitors for solid tumours, the news source said.

To read more NewsPoints articles, click here.